{"nctId":"NCT03824587","briefTitle":"Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy","startDateStruct":{"date":"2019-02-28","type":"ACTUAL"},"conditions":["Hyperphosphatemia"],"count":236,"armGroups":[{"label":"Tenapanor 30 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Tenapanor","Drug: Phosphate Binder Agents"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Phosphate Binder Agents"]}],"interventions":[{"name":"Tenapanor","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Phosphate Binder Agents","otherNames":["sevelamer carbonate","ferric citrate","calcium carbonate","calcium acetate","sucroferric oxyhydroxide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed and dated informed consent prior to any study specific procedures.\n* Males or females aged 18 to 80 years, inclusive, at Screening\n* Females must be non-pregnant, non-lactating and either be post-menopausal for at least -2 months, have documentation of irreversible surgical sterilization, use of acceptable -contraceptive method, or sexual abstinence, or a sterile sexual partner from Screening -until 30 days after the last subject visit.\n* Males must agree to avoid fathering a child (or donating sperm), and therefore be either sterile (documented) or agree to use approved methods of contraception, from the time of enrollment until 30 days after end of study.\n* Chronic maintenance hemodialysis (HD) 3x/week for at least 3 months or chronic maintenance peritoneal dialysis (PD) for a minimum of 6 months.\n* If receiving active vitamin D or calcimimetics, the dose should have been unchanged for the last 4 weeks prior to Screening.\n* Kt/V ≥1.2 at most recent measurement prior to Screening.\n* Prescribed and taking phosphate binder medication at least 3 times per day, and the prescribed dose should have been unchanged during the last 4 weeks prior to Screening.\n* Serum phosphorus levels must be ≥5.5 and ≤10.0 mg/dL at Screening and the end of the run-in period, analyzed at the central laboratory used in the study.\n\nExclusion Criteria:\n\n* Severe hyperphosphatemia defined as having an s-P level \\>10.0 mg/dL on phosphate-binders at any time point during routine clinical monitoring for the 3 preceding months before Screening.\n* Serum/plasma parathyroid hormone \\>1200 pg/mL.\n* Clinical signs of hypovolemia at Screening as judged by the Investigator.\n* History of inflammatory bowel disease (IBD) or irritable bowel syndrome with diarrhea (IBS-D).\n* Scheduled for living donor kidney transplant or plans to relocate to another center during the study period.\n* Use of an investigational agent within 30 days prior to Screening.\n* Involvement in the planning and/or conduct of the study (applies to both Ardelyx/Contract Research Organization (CRO) staff and/or staff at the study site).\n* If, in the opinion of the Investigator, the subject is unable or unwilling to fulfill the requirements of the protocol or has a condition which would render the results uninterpretable.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Serum Phosphorus (s-P) Level From Baseline to Week 4.","description":"Difference in mean change from baseline in s-P level at Week 4 between the tenapanor and placebo groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"0.131"},{"groupId":"OG001","value":"-0.19","spread":"0.130"}]}]}]},{"type":"SECONDARY","title":"s-P Response at Week 4","description":"Achieving an s-P level \\<5.5 mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline in iFGF23 at Week 4","description":"iFGF23 at Week 4/baseline iFGF23 - 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.756","spread":null},{"groupId":"OG001","value":"0.931","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline in cFGF23 at Week 4","description":"cFGF23 at Week 4/baseline cFGF23 - 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.779","spread":null},{"groupId":"OG001","value":"0.947","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":117},"commonTop":["Diarrhea"]}}}